Re: my semi-annual review of GERN
GERN appears overbought in my opinion. The company needs to raise more capital via dilution if it wants to stay independent and pay its growing workforce. The question is when did the standard FDA review process become known by Chippy as opposed to the expectation of priority review? And when did Chippy start selling shares in the open market!? That is the billion dollar question. Shareholders need to know.